CN Patent

CN113372290A — 一种药物Tafamidis的合成方法

Assigned to Zunyi Medical University · Expires 2021-09-10 · 5y expired

What this patent protects

一种药物Tafamidis的合成方法，所述合成方法以3‑羟基‑4‑胺基苯甲酸为原料，经酯化、酰胺化、环合以及水解反应制备药物Tafamidis。该方法利用浓硫酸和甲醇替代较昂贵和较危险的三甲基硅重氮甲烷进行羧基的甲基化反应；在环合反应中，显著降低了对甲苯磺酸的用量；简化了反应后处理，每步反应均不需要柱层析纯化产物且显著提升了反应的总产率，更适宜工业化生产。

USPTO Abstract

一种药物Tafamidis的合成方法，所述合成方法以3‑羟基‑4‑胺基苯甲酸为原料，经酯化、酰胺化、环合以及水解反应制备药物Tafamidis。该方法利用浓硫酸和甲醇替代较昂贵和较危险的三甲基硅重氮甲烷进行羧基的甲基化反应；在环合反应中，显著降低了对甲苯磺酸的用量；简化了反应后处理，每步反应均不需要柱层析纯化产物且显著提升了反应的总产率，更适宜工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN113372290A
Jurisdiction
CN
Classification
—
Expires
2021-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Zunyi Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.